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studies or participate in joint projects, whereas 69% plan to conduct HSR studies in 
the near future. All these numbers increased since the last surveys. ConClusions: 
The results of the survey clearly pointed out the high and still increasing importance 
of HSR and real-life studies also in the health care industry. Although a considerable 
amount of uncertainty concerning the specific methodological requirements remain 
it is widely accepted that the quality of data and analyses is crucial for acceptance 
by payers. As HSR projects require considerable human and financial resources alli-
ances and joint projects between industry, academia and payer are aspired.
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objeCtives: In France, drugs and medical devices costs concern an important part 
of health care expenditure. Several reforms have been put in place over the past 
years in order to limit these expenditures, in particular price cutting policy. Cost-
effectiveness assessment was integrated in France in the market access scheme 
of health products by the Social Security Financing Act for 2012 and is required 
since October 3rd 2013. This new mission was assigned to the Health Economics 
and Public Health Committee (CEESP) of the French National Authority for Health 
(HAS) and is become compulsory for innovative health products and are likely to 
have a significant impact on the health insurance expenditures. The objectives of 
this work were to see how the cost-effectiveness assessment has been integrated in 
France and to discuss the impact of this assessment on the health products market 
access. Methods: The work consists in analyzing the process of the economic 
evaluation achieved by the HAS since October 3rd 2013. Results: Economic evalu-
ation is a new step in the market access scheme. In order to respect the legislated 
timeframe of 90 days, it is simultaneously conducted with the medical assessment 
by the Transparency Commission of the HAS. For each health products, an efficiency 
opinion is delivered by the CEESP. It presents the methodological conformity accord-
ing to HAS guidelines and a conclusion about the efficiency, on the basis of the 
Incremental Cost-Effectiveness Ratio (ICER). Currently, 15 dossiers were eligible for 
cost-effectiveness assessment. First assessments permit to confirm that the pro-
cedure is operational. The average processing time was 94,8 days. ConClusions: 
In France without efficiency threshold value, the CEESP can’t conclude absolutely 
on the efficiency of health product. We don’t know how the ICER will be considered 
by the French Healthcare Products pricing Committee (CEPS) at the time of pricing 
negotiation with the pharmaceutical industry.
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objeCtives: In France, cost-effectiveness assessment is required since October 3rd 
2013 for innovative health products and are likely to have a significant impact on 
the health insurance expenditures. The objective of this work is to report first cost-
effectiveness assessments, achieved by the Health Economics and Public Health 
Committee (CEESP) of the French National Authority for Health (HAS). Methods: 
The investigation consists in analyzing medico-economic dossiers submitted at 
the CEESP between October 2013 and October 2014. This analysis is based on the 
opinion delivered by the CEESP, the methodology used in the model and the pro-
cess of the assessment achieved by the HAS. Results: At the time of writing the 
abstract, 15 dossiers were eligible for cost-effectiveness assessment. All dossiers 
were based on cost-utility models. Two dossiers presented a negative opinion due 
to the methodological conformity according to HAS guidelines. For dossiers with 
a positive opinion, the Incremental Cost-Effectiveness Ratio (ICER) were between 
5 866€ /QALY (for a subgroup analysis) and 194 531 € /QALY. Main methodological 
reserves made by the CEESP concerned comparators, time horizon, robustness of 
clinical data, utility measures. The average processing time was 94,8 days. For the 
moment, no price has been published in the Official Journal. ConClusions: The 
first assessments permit to confirm that the procedure is operational. In light of 
these first assessments, an update of the HAS methodological guidelines should 
be done. In France, without efficiency threshold value, the CEESP can’t conclude 
absolutely on the efficiency of health products. Thus, we don’t know what will be 
the place of the ICER in the pricing negotiation between the pharmaceutical industry 
and the French Healthcare Products pricing Committee (CEPS).
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objeCtives: The objective of this research is to provide an overview of the regula-
tory process of medical devices in China. Potential challenges related to medical 
device registration and major policy changes are highlighted especially since the 
restructuring of the China FDA in March 2013. The results of this research are aimed 
at informing regulatory bodies, health policy decision makers, national and interna-
tional Health Technology Assessment networks, as well as medical devices manu-
facturers. Methods: A systematic review was conducted from 2009-2013 to identify 
the challenges and opportunities in the Chinese medical device regulatory process 
searching the PubMed, Science Direct, Scopus databases and Zhongguozhiwang. 
The PRISMA guidelines were applied for the search. In addition, an analysis of 
PHP58
tHeraPeutIC PosItIonIng rePort: new CollaBoratIve network of 
Drug assessment In sPaIn - tHe start of P&r BaseD on relatIve 
effeCtIveness?
Paladio N., Cortés I., Gil A., Crespo C.
Boehringer Ingelheim, Sant Cugat del Vallès (Barcelona), Spain
objeCtives: Therapeutic Positioning Reports (TPRs) were introduced to the 
Spanish P&R process in May 2013. TPRs evaluate comparative efficacy and safety 
and introduce usage and monitoring criteria for new drugs and existing drugs seek-
ing reimbursement. The procedure was set-up by the Spanish Medicines Agency 
(AEMPS) and the Ministry of Health with the aim to accelerate the P&R process 
and to generate a single, national relative effectiveness report avoiding additional 
regional evaluations, contributing to reducing the long-delays in market access 
timelines experienced in the last few years. The objective of this ongoing work 
is to describe and analyze both the metrics of the process and the contents and 
results of TPRs. Methods: Descriptive study based on public information available 
from the European and Spanish Medicines Agencies (May 2013-ongoing). Results: 
From June 2013 to May 2014 the Therapeutic Positioning Coordinating Group 
(TPCG) has officially launched 60 TPR plus 7 use protocols (UP) at the request of 
the Interministerial Price Council (IMPC). 75% of TPR involve new chemical enti-
ties (82% of those with a positive opinion from the CHMP between May 2013-April 
2014) and assess a single entity (48% specialty care) indicated, mainly, for patients 
with neoplastic (28%) and endocrine (18%) diseases. All UP affect targeted therapies 
with approval between Jan2010-Dec2012. Since its establishment in May 2013, the 
TPCG has released 26 TPR (57% of those expected according to the pre-established 
procedure -3 months working time) with a median release time of 7,1 months. Only 
1 has been published. The rest await for P&R decisions. Other 5 pilots have been 
published in parallel. In total 5 TPR recommend to further restrict the European 
label. ConClusions: TPR are not being released at the expected rate. Follow up is 
necessary to predict its impact in P&R and market access in regions across Spain.
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objeCtives: Medical devices constitute a set of important health technologies for 
the care of patients. While there are similarities between some reimbursement 
systems, each market has its own unique characteristics. This article focuses on 
the reimbursement procedures for medical devices in the DACH countries (Austria, 
Germany, Switzerland), and aims at finding commonalities in payer requirements 
and reimbursement pathways. Methods: Reimbursement application pathways 
for inpatient and outpatient medical devices were evaluated for Austria, Germany 
and Switzerland. The key items being analysed for similarities and differences in 
each setting were transparency, clinical and health economic evidence require-
ments, submission timelines and the length of the whole reimbursement appli-
cation process. Results: In the inpatient setting, the evidence requirements for 
clinical data are different between the analysed countries: The lowest clinical evi-
dence requirements are seen in Germany, while the highest are given in Switzerland 
(in some scenarios). In terms of health economics the requirements are medium 
to low. A medium rating was given for Austria and Switzerland (in some scenarios) 
as a health economic analysis is required (e.g. cost comparison), and a low rat-
ing was applied to Germany as limited economic information (cost assessment/
comparison) needs to be submitted. The length of the application process is well 
defined in Austria and Germany and vague in Switzerland. In the outpatient setting 
the requirements for clinical and health economic data are significantly increas-
ing. Clinical requirements are getting close to pharmaceutical methods whereas 
health economic evidence is requested in all DACH countries. The length of the 
reimbursement process is not clearly defined in all three countries. ConClusions: 
Despite varying reimbursement processes within the DACH region, there are some 
important similarities between the evidence requirements which may help manu-
facturers to guide market access and reimbursement strategy decisions in order 
to drive successful submissions and applications of innovative medical devices.
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objeCtives: The necessity for manufacturer of pharmaceuticals and medical 
devices seem to deal with health services research (HSR). Health care reform acts 
and revisions of HTA method guidance documents in many European countries 
continue to point out the importance of real-life consequences. The objective of the 
study was to evaluate the self-reported importance and the own activities of phar-
maceutical companies in Germany concerning health services research. Methods: 
Between December 2013 and February 2014 an online survey among members of 
the German Pharmaceutical Industry Association (BPI) was accomplished. Similar 
surveys were conducted in 2009 and 2011. Results: 59% of 109 addressed com-
panies took part in the survey. The participants were representative for Germany 
concerning research-orientation, size and type of products. For 88% of the participat-
ing companies HSR is of importance. This high rate remained constant compared 
to the last surveys. For most of the companies HRS yields valuable contributions 
for the negotiations with payers (96%), in the AMNOG evaluation process (89%) and 
for optimization of placement of marketed products (94%). 50% of the companies 
conducted HSR studies over the last years, respectively are currently conducting HSR 
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  A415
Region to legislate on the matter, supporting the prescription of the biosimilar to the 
naive patient. The aim of this study was to evaluate the impact of cost-containment 
policies about biosimilars in Campania between 2009 and 2013. Methods: IMS 
Health regional database was used to carry out this descriptive retrospective drug-
utilization for the years 2009 through 2013. Information was retrieved about differ-
ent distribution channels (retail, direct distribution, hospital). Consumptions are 
expressed in Counting Units (CU) and trends have been calculated using Compound 
Average Grow Rate (CAGR). Results: In 2013, a total consumption of 930.859 CU of 
biosimilar drugs was registered in Italy (CAGR 13/09 68,8%). The penetration rate of 
biosimilar was 23,9% with regard to expenditure and 25,3% with regard to consump-
tion. Analyzing the consumption of biosimilars by therapeutic category in Italy, 
the consumption of erythropoietin and filgrastim has an index of annual growth 
respectively equal to 153.4% and 174.7%. In Campania, the penetration rate of all 
biosimilars was 31.4% of total expenditure and 35.9% of consumption. Analyzing 
the trend in consumption for single therapeutic category, it can be seen that pen-
etration is due to erythropoietin (297.5% CAGR); with regard to filgrastim, however, 
the average annual growth rate is around 54%. ConClusions: The results suggest 
that Campania Region records an index of market penetration of biosimilars higher 
than the national. This trend could be attributable to the cost-containment policies 
implemented in the region.
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objeCtives: to assess the consequences in terms of outpatient pharmaceutical 
expenditure, that accounted for changes in state law on de-funding of medicines 
and the introduction of pharmaceutical co-payment in 2012 in Spain. Methods: 
Cross-sectional study during 2012. Two health regions of Spain (Comunitat Valenciana 
with 5,129,266 inhabitants and Extremadura with 1,108,130. Total population: 
6,237,396) where analysed to determine the evolution of outpatient pharmaceuti-
cal expenditure after a change in state law (July 1,2012). We compared the first over 
the second half of 2012 by age and gender distinction. Results: The total spending 
was reduced by 16.80% after the new law. By gender, the reduction was greater in 
women (17.47% versus 15.25%). By age, the decrease was seen most sharply in the 
stretch of paediatrics (0 to 14 years). In older people, the stretch mostly affected 
was the one from 66 to 70 years old. The stretches with fewer changes in terms of 
outpatient pharmaceutical expenditure were 21-25 years (reduced by 5.42%) and 
46-50 years (reduced by 6.07%). ConClusions: After the de-funding of 400 drugs 
and the increase of pharmaceutical co-payment (40% previously and now variable, 
40%, 50% and 60% depending on income levels), a drastic drop in the amount of 
pharmaceutical outpatient expenditure is observed. Further analysis is required 
in order to assess whether that decline is sustained over time or, on the contrary, a 
new phase of positive growth begins.
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objeCtives: The Food and Drug Administration (FDA) issued a safety announce-
ment on January 10,2013 requiring manufacturers to lower the recommended dose 
of zolpidem for women. Lower dose recommendations for elderly patients were 
already labeled. This analysis describes the impact of the FDA safety announcement 
on the initial dose dispensed to new zolpidem users. Methods: Patients > = 18 
years old with an immediate- (IR) or extended-release (ER) zolpidem prescription 
between July 2012 and July 2013 were evaluated using MarketScan Commercial 
and Medicare Supplemental Databases. The first zolpidem prescription during the 
pre-warning (July 1, 2012 – Jan. 9, 2013) and post-warning (Jan. 10, 2012 – July 31, 2013) 
time periods was evaluated. Chi square tests were used to examine differences in 
the proportion of new users dispensed low dose zolpidem during each of the time 
periods. Results: Overall a significantly higher proportion of patients in all age 
gender groups received low dose IR zolpidem during the post-warning compared 
to the pre-warning period. Similar results were found for the ER formulation except 
among males 65 years or older. Before and after the FDA safety warning, the high-
est proportion of patients receiving low dose zolpidem (any formulation) for their 
first prescription was among elderly women (46% pre-warning; 53% post-warning). 
Even after the FDA warning, a large proportion of women 18 to 64 years old (63% IR; 
65% ER) and women 65 years or older (46% IR, 55% ER) received high dose zolpidem 
for their first prescription. ConClusions: For all age and gender categories, the 
proportion of patients receiving low dose zolpidem increased after the FDA safety 
warning issued in 2013. The highest proportion of low dose zolpidem use was seen 
in elderly females. However, the proportion of women and elderly who received low 
dose zolpidem even after the FDA safety warning was still relatively low.
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objeCtives: Medications in households offer a variety of opportunities for irra-
tional consumption and development of adverse drug reactions (ADR). One of the 
medicines most commonly associated with ADR are non-steroidal anti-inflam-
matory drugs (NSAIDs), one of the most frequently used medications in Serbia. 
Therefore, the aim of this study was to analyze the amount and structure of 
previous and current policies and regulations in the grey literature was conducted 
for this research. Results: 17 articles were included in the systematic review. The 
three most crucial issues in the regulatory process have been analyzed in detail 
and relate to products technical requirements, the type test report and the clinical 
trials evaluation. Concerning the ‘products technical requirements’ and the ‘type 
test report’, the main challenges are related to the lack of sufficient legal status 
and openness for interpretation. A new Regulation governing the Supervision and 
Administration of medical devices introduced in June 2014 now includes improve-
ments regarding specification of requirements. In addition, if a medical device ful-
fills certain requirements, it should be exempted from clinical trials, which signifies 
a major simplification for manufacturers. ConClusions: Getting a medical device 
registration certificate in China is a complicated, time-consuming process. The new 
regulatory policies in place focus more strongly on the clinical effectiveness and 
safety of medical devices. However, some major structural problems remain, i. e. 
the lack of technical standards for manufacturers, with major policy planning and 
changes currently underway in order to address these problems.
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objeCtives: The Medical Technologies Evaluation Programme (MTEP) was set up 
by NICE in 2009 to identify new medical devices and diagnostics that could improve 
patient experience and outcomes whilst driving health care efficiencies. Innovative 
products are submitted by manufacturers for evaluation, requiring confidence in 
the programme and its methods. The purpose of the study was to examine the 
experiences of manufacturers whose products have been assessed by MTEP, to 
review the challenges of the submission process, the resources required for the 
submission, NICE support for further evidence generation, and the impact of NICE 
recommendations on product uptake in the UK and elsewhere. Methods: A sys-
tematic review of published literature on MTEP and products/companies that have 
been through this process was completed. Qualitative interviews were then under-
taken with a representative sample of senior team members from manufacturers 
whose products have undergone MTEP review to elicit insight on their perceptions 
and experiences of the programme. Findings were collated and analysed themati-
cally. Results: Manufacturers have identified the benefits of submitting to MTEP 
in terms of value communication in the NHS, however key issues are: the signifi-
cant time and resource burden of completing the submission, the lack of funding 
for additional data generation where this is required, the challenges of adhering 
to the stringent timescale, and the questionable benefits of submitting for larger 
companies with extensive sales teams. There is also a recognised need for greater 
efforts to influence practice and prescribing decisions in the NHS based on the MTEP 
guidance. ConClusions: Manufacturer experience of the MTEP process is largely 
positive, however as MTEP is dependent on manufacturers to initiate submissions, 
key actions can be taken to incentivise future submissions. Priorities will be ensur-
ing that MTEP recommendations have a tangible and proven impact on prescribing 
decisions and that support is available for the submission development.
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objeCtives: Risk sharing agreements are among the new trends in pharmaceutical 
sector as a tool for reducing the drug expenditures and increasing patient access 
to innovative drugs. The objective of this study is to elaborate the availability of 
risk sharing agreements in the Turkish pharmaceutical sector. Methods: A lit-
erature review was undertaken to identify the existing risk sharing schemes in the 
European countries using “risk sharing agreements”, and risk sharing schemes” as 
key words. Results: Risk sharing agreements are mainly classified as financial 
based and performance based schemes. The vast majority of those agreements are 
implemented in oncology area, others are mostly implemented in ophthalmology, 
blood diseases and multiple sclerosis areas. Countries mostly prefer financial based 
schemes as they are easier to implement and track. Performance based agreements 
are relatively rare as they are more complicated due to the long length of follow up, 
lack of reliability of data generation/registration, administrative burden for all stake-
holders. ConClusions: Taking into account that original drugs to be reimbursed 
in Turkey need to grant a compulsory statutory discount which is generally 41%, 
it can be stated that Turkey is already implementing a financial based scheme. On 
the other hand, when availability of performance based risk sharing agreements is 
assessed, there is a lack of infrastructure to track drugs or non-responders and also 
it seems to be difficult to make this kind of agreements in Turkey without making 
any amendments in current regulations. In addition to these regulation issues, 
transaction and administrative costs should also be taken into account. On the 
other hand despite these difficulties, these schemes could provide budget control 
and patient access to highly innovative and expensive treatments.
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objeCtives: The expiration of biotech drugs patents has led to the creation of 
drugs copies of originator products, defined biosimilars. The automatic substitut-
ability between the originator and the biosimilar is not allowed in Europe with the 
exception of France. In Italy, in the absence of a national legislation, some Regions 
have issued directives to the spread of the biosimilar use. Campania was the first 
